After the National Day, the pharmaceutical industry began to enter the third quarterly performance disclosure period, including China Resources Pharmaceutical, Kangyuan Pharmaceutical and other pharmaceutical companies have announced the third quarter of 2022 performance data
.
Pharmaceutical industry (Image source: Pharma.
com)
Many pharmaceutical companies ran out of "acceleration" in the first three quarters
Recently, the third quarter report of 2022 released by Kangyuan Pharmaceutical showed that the operating income was 1.
028 billion yuan, a year-on-year increase of 26.
25%; The net profit was 70.
2172 million yuan, a year-on-year increase of 47.
48%.
China Resources Sanjiu announced on the evening of October 10 that the company achieved total operating income of 12.
111 billion yuan in the first three quarters of 2022, a year-on-year increase of 7.
53%; The net profit attributable to the shareholders of the listed company was 1.
952 billion yuan, a year-on-year increase of 11.
17%.
Overall, most of the pharmaceutical companies that have disclosed their performance have achieved "acceleration"
in the first three quarters.
In addition, according to the 2022 third quarter report forecast disclosure schedule, in October, a large number of pharmaceutical companies such as Berry Genetics, Chenxin Pharmaceutical, Wantai Biotechnology, Guobang Pharmaceutical, Shuoshi Biotechnology, Huangshan Capsule, Sanxin Medical, Poinsettia, Jimin Medical, Weili Medical, ProPharmaceutical, Huaren Pharmaceutical and other pharmaceutical companies will soon disclose their third quarterly results
.
Generally speaking, companies that release performance data first tend to have better results
.
The newly released research report of Industrial Securities pointed out that according to preliminary analysis, the performance of the pharmaceutical sector in the third quarter still continued to grow relatively stable and rapidly, and from a breakdown point of view, it is expected that Q3 of the upstream life sciences, ophthalmic optometry, some domestic alternative medical devices, CXO, some vaccines, pharmacies and other sectors is expected to achieve better performance growth
.
The market situation of the sector in the fourth quarter is still optimistic about brokerages
In the long run, many securities firms, including Deppon Securities, Soochow Securities, and Kaiyuan Securities, still expressed their optimism about the market of the pharmaceutical sector in the fourth quarter, and suggested paying attention to the tracks
of traditional Chinese medicine, consumer medical care, innovative drugs, and medical devices in the sub-sectors.
Specifically, the current valuation of the Chinese medicine sector is low, the performance of Chinese medicine companies on the track is relatively stable, and Chinese medicine is a national treasure, which has been supported
by a series of favorable policies in recent years.
The industry expressed optimism about the vitality of the reform of state-owned enterprises of traditional Chinese medicine enterprises, as well as the modernization direction
of traditional Chinese medicine through formula granules and new Chinese medicines.
The key track direction focuses on innovative Chinese medicines, branded Chinese medicines and Chinese medicine formula granules
.
In the post-epidemic era, with the continuous upgrading of consumption levels, some opportunities
will emerge in the consumer medical track.
From the perspective of the holdings of head medical public funds, among the positions of the managed funds of Gülen and Zhao Bei in the second quarter, Tongrentang has newly joined the list of heavy stocks; ICBC Frontier Medical Fund managed by Zhao Bei, Tongrentang and Kanglong Chemical among the heavy stocks are also new stocks
.
It is not difficult to see that these public funds are optimistic about the future trend of consumer healthcare
.
Innovative drugs are also a track that has attracted much attention, since the new policy in the second half of 2021 to combat "pseudo-innovation", the market has gradually calmed down, after more than a year of adjustment, the innovative drug market has picked up, the policy side includes the simple renewal of innovative drugs, innovative drugs to encourage some single-arm clinical trials, innovative drugs DRG exemption and a series of policies have been released, the industry believes that this will contribute to the healthy and high-quality development of the domestic innovative drug industry.
Pharmaceutical companies that are innovative and differentiated in their products and bring value in line with the real clinical needs of patients are expected to gain opportunities
.
In addition, recently, the medical device industry continues to usher in favorable policies, among which the national and local finances have given sufficient financial support for new medical infrastructure, which may be expected to help the volume of
medical devices.
Kaiyuan Securities expects that the performance of the medical device sector in the third quarter will continue to improve year-on-year, and the fourth quarter is expected to usher in a valuation switch.
Founder Securities believes that the new policy will promote the peak period of medical equipment procurement in
the fourth quarter of this year and next year.
On the track, leading enterprises with strong independent innovation and research and development capabilities and product capabilities are worth paying attention to
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
